Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 April 1994 | Volume 120 Issue 7 | Pages 576-578
May [5] listed 81 distinct causes of peripheral facial nerve palsies, including traumatic, infectious, and metabolic. Idiopathic Bell palsy accounted for 57% of the 1575 cases he himself reported. Peripheral facial nerve palsy is associated with nonmalignant parotitis. Andrews and colleagues [6] found only 10 reported cases and presented three more. Our extensive MEDLINE search failed to reveal any previously reported associations between facial nerve palsy and radioiodine treatment. We present two cases of facial nerve palsies in patients who developed parotitis after radioiodine therapy.
BRIEF REPORT
Peripheral Facial Nerve Palsy after High-Dose Radioiodine Therapy in Patients with Papillary Thyroid Carcinoma
Sialoadenitis is a frequent complication of radioiodine treatment, occurring clinically in 10% of patients [1], although biochemical alterations of saliva are present 100% of the time [2]. This is caused by the similar iodine avidity of the salivary gland and thyroid tissue, each achieving a tissue-to-serum ratio of approximately 50 [3]. Administration of thyroid-stimulating hormone can cause a tenfold increase in thyroid iodine uptake [4].
|
Case Reports
|
|---|
|
|
|---|
A 51-year-old man had locally invasive (stage 2) papillary thyroid carcinoma, for which he was treated with a thyroidectomy with lymph node dissection. Nineteen years later, he had a second operation for recurrent disease, which was followed by 1070 MBq (29 mCi) of iodine-131.
One year later, he had a radioiodine dosimetry with a thyroid-stimulating hormone of 134 mU/L. The 24-hour thyroid bed and right and left parotid gland uptakes were 2.4%, 9.6%, and 6.9%, respectively. When we retrospectively analyzed the available data points, using Medical Internal Radiation Dose techniques [7], we estimated that the radiation dose delivered with 9620 MBq (260 mCi) to the recurrent thyroid cancer, the right and left parotid glands, and the blood were 112 000, 21 000, 13 500, and 200 rad, respectively.
The patient developed severe sialoadenitis with marked engorgement and tenderness of the parotids within 24 hours and lost taste sensation 3 to 4 days later. After 9 days, he developed a partial right peripheral facial nerve palsy and was treated with a 5-day course of prednisone. A magnetic resonance imaging scan of the face showed no abnormalities. At 3 months' follow-up, he had nearly total recovery of facial nerve function but had persistent xerostomia.
Patient 2
|
|---|
Discussion
|
|---|
|
|
|---|
The first patient lost taste sensation. Rarely, patients with Bell palsy report an alteration in taste sensation, which is thought to represent concurrent inflammation of the chorda tympani. Alteration in taste is a common complaint in patients having radioiodine treatment. The exact mechanism is uncertain, but decreased saliva production and altered composition have been proposed. Typically, the chorda tympani branches separate from the facial nerve 4 mm proximal to the stylomastoid foramen. Thus, it is unlikely that parotitis should involve the chorda tympani.
Inflammation involving the facial nerve could have caused the development of the paralyses in our patients. Lee described the development of vocal cord paralysis after radioiodine therapy and postulated that it was caused by local inflammation [10]. However, the onset of weakness occurred at least a week after the peak inflammation and several days after the clinical resolution of parotitis. Further, the patients differed in the degree of salivary gland uptake and clinical sialoadenitis (Figure 1). Neither patient had clinical evidence of tumor infiltration of the parotid glands.
Another possible explanation is direct radiation injury to the facial nerve. The ß radiation from iodine-131 penetrates approximately 2 to 3 mm. Thus, highly concentrating parotid tissue surrounding a strategic point along the nerve or vaso nervosum could have caused sufficient damage.
Conclusion
|
|---|
|
|
|---|
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication. J Nucl Med. 1984; 25:755-8.
2. Maier H, Bihl H. Effect of radioactive iodine therapy on parotid gland function. Acta Otollaryngol (Stockh). 1987; 103:318-24.
3. Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. 6th ed. Philadelphia: J.B. Lippincott; 1991:53.
4. Wolff J, Halmi NS. Thyroidal iodine transport: V. The role of Na±K±activated, ouabain-sensitive adenosinetriphosphatase activity. J Biol Chem. 1963; 238; 847-51.
5. May M. The Facial Nerve. New York: Thieme, Inc.; 1986:182-3.
6. Andrews JC, Abemayor E, Alessi DM, Canalis RF. Parotitis and facial nerve dysfunction. Arch Otolaryngol Head Neck Surg. 1989; 115; 240-2.
7. Loebinger R, Budinger TF, Watson EE; eds. MIRD Primer for Absorbed Dose Calculations. New York: Society of Nuclear Medicine; 1988.
8. Earll JM, Kolb FO. Facial paralysis occurring with hypothyroidism. A report of two cases. Calif Med. 1967; 106; 56-8.
9. Cox NH, Chew D, Williams JG, Morris AI. Bell's palsy associated with hypothyroidism. Br J Clin Pract. 1985; 39; 158-9.
10. Lee TC, Harbert JC, Dejter SW, Mariner DR, VanDam J. Vocal cord paralysis following I-131 ablation of a postthyroidectomy remnant. J Nucl Med. 1985; 26; 49-50.
This article has been cited by other articles:
![]() |
L. Mandel and F. Liu Salivary Gland Injury Resulting From Exposure to Radioactive Iodine: Case Reports J Am Dent Assoc, December 1, 2007; 138(12): 1582 - 1587. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Walter, C. P. Turtschi, C. Schindler, P. Minnig, J. Muller-Brand, and B. Muller The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study J. Nucl. Med., October 1, 2007; 48(10): 1620 - 1625. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Solans, J.-A. Bosch, P. Galofré, F. Porta, J. Roselló, A. Selva-OCallagan, and M. Vilardell Salivary and Lacrimal Gland Dysfunction (Sicca Syndrome) After Radioiodine Therapy J. Nucl. Med., May 1, 2001; 42(5): 738 - 743. [Abstract] [Full Text] |
||||
![]() |
E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||